Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Finland

European Innovation Council · Running

Bioalbumen Novel precision fermentation process to produce animal-free bioidentical ovalbumin

Coordinator
Onego Bio Ltd, Finland
Runs
1 January 2025 to 31 December 2026
Status
Running
EU funding
€2.5m
Total cost
—
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
101188965

What the project is doing

In the project's own words, from its summary on CORDIS.

Eggs are critically important in the global food system due to functional and nutritional properties; yet the egg market and supply chains are in crisis due to cage-free requirements and avian flu. Onego Bio will make it possible to manufacture egg protein entirely animal-free. We developed a highly-scalable precision fermentation process using the patented Trichoderma reesei cellular-based production to produce animal-free ovalbumin.

We produce bioidentical egg protein with cost parity and 87% lower CO2 emissions compared to traditional animal-derived eggs. Ovalbumin is the most important egg protein, responsible for the essential ingredient performance. This single protein ovalbumin can solve all current challenges in the egg market and supply chain. Our product, Bioalbumen provides the nutritional and functional upsides of egg protein, without the environmental, ethical and safety-related drawbacks.

Our manufacturing method stabilises the food supply chain and increases food security.

Topics

Who is involved

OrganisationCityCountryRole
Onego Bio LtdHelsinkiFinlandCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI